Results 221 to 230 of about 104,287 (300)

Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT The approval of baricitinib and ritlecitinib for alopecia areata (AA) marks the beginning of the Janus kinase (JAK) inhibitor era in AA treatment. Tofacitinib, a first‐generation JAK1/3 inhibitor, has theoretical potential to treat AA; however, real‐world evidence, particularly on comparative outcomes across patient subgroups and patient ...
Yifan Jin   +7 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 841-855, May 2026.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Viral mechanisms, tropism, and clinical relevance regarding the ophthalmic manifestations of SARS-CoV-2 infection. [PDF]

open access: yesInt J Ophthalmol
González S   +5 more
europepmc   +1 more source

Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 876-886, May 2026.
AD is a relapsing and remitting skin disease often requiring long‐term treatment. We assessed the long‐term efficacy of tralokinumab in adults with moderate‐to‐severe AD consistently treated for up to 4 years. Treatment with tralokinumab plus optional TCS/TCI provided substantial improvements in AD signs and symptoms, and these improvements were ...
Melinda Gooderham   +13 more
wiley   +1 more source

Assessment of the Advancement of Alveolar Bone Loss in Canine Patients Receiving Definitive Radiotherapy for Sinonasal Tumors

open access: yesVeterinary Radiology &Ultrasound, Volume 67, Issue 3, May 2026.
ABSTRACT Radiotherapy for the treatment of sinonasal tumors in dogs is generally well tolerated, but the range of long‐term adverse effects remains poorly understood. In people receiving radiation for head and neck tumors, existing dental disease is a predisposing factor for radiation‐induced oral complications that can lead to worsening periodontal ...
Erin Paul‐Stewart   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy